Subsequent studies identified mutations in either IDH1 or IDH2 in over 70% of lower-grade gliomas, as well as a small subset (~5%) of secondary glioblastomas that evolved from lower-grade precursors (106). This evidence concerns the gene IDH1 and central nervous system cancer.